The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEAP1 mutated renal cell carcinoma (RCC): Characterization of an emerging molecularly defined RCC subtype.
 
Marie Carlo
Honoraria - OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Other Relationship - Kidney Cancer Association; Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Ying-Bei Chen
Consulting or Advisory Role - Inspirna
 
Andrea Knezevic
Consulting or Advisory Role - ByHeart
 
Grace Zong
No Relationships to Disclose
 
Ziad Bakouny
Honoraria - UpToDate
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
(OPTIONAL) Uncompensated Relationships - ASCO IMG Community of Practice; Dana-Farber Cancer Institute; IMG Oncologists (NGO)
 
Yelena Kemel
No Relationships to Disclose
 
Alicia Latham
No Relationships to Disclose
 
Ying Liu
Consulting or Advisory Role - Myriad Genetics
Research Funding - Artios (Inst); AstraZeneca (Inst); Repare Therapeutics (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Myriad Genetics
 
Neil Shah
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst); Exelixis; HiberCell (Inst)
Travel, Accommodations, Expenses - Merck
 
Darren Feldman
Consulting or Advisory Role - BioNTech; Debiopharm Group; Exelixis; Renibus Therapeutics; Telix Pharmaceuticals; Xencor
Research Funding - Bristol-Myers Squibb/Roche; Decibel Therapeutics (Inst); Exelixis; Telix Pharmaceuticals
Other Relationship - UpToDate
 
Ritesh Kotecha
Consulting or Advisory Role - Eisai; Eisai; Guidepoint Inc; Guidepoint Inc
Research Funding - Allogene Therapeutics (Inst); ArsenalBio (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Xencor (Inst)
 
Miika Mehine
No Relationships to Disclose
 
Diana Mandelker
No Relationships to Disclose
 
Zsofia Stadler
Consulting or Advisory Role - Adverum (I); Genentech/Roche (I); Neurogene (I); Novartis (I); Optos (I); Outlook Therapeutics (I); Regeneron (I)
Patents, Royalties, Other Intellectual Property - Intellectual property rights (SOPHiA Genetics) (Inst)
Other Relationship - JCO Precision Oncology, Associate Editor; UpToDate, Section Editor
 
Eduard Reznik
No Relationships to Disclose
 
Michael Berger
Honoraria - SOPHiA Genetics
Consulting or Advisory Role - AstraZeneca; PAIGE.AI
Research Funding - Boundless Bio
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Martin Voss
Consulting or Advisory Role - Affimed Therapeutics; AstraZeneca; AVEO; Eisai; Exelixis; Merck; Oncorena
Research Funding - Exelixis; Pfizer; Regeneron
(OPTIONAL) Uncompensated Relationships - Aravive; AstraZeneca; BMS; Genentech/Roche; NiKang Therapeutics
 
Robert Motzer
Consulting or Advisory Role - Aveo; EMD Serono; Exelixis; Incyte; Merck; Takeda
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
A. Hakimi
Research Funding - Merck